Jaguar Health

What Jaguar Health does

Jaguar Health is a commercial-stage pharmaceutical company that discovers, develops, and commercializes plant-based prescription medicines derived primarily from the Croton lechleri Amazonian tree (dragon's blood/sangre de drago). Its core technology is crofelemer, a first-in-class antisecretory agent that modulates chloride secretion in the gastrointestinal tract by targeting CFTR and CaCC ion channels; it is the first oral drug approved under the FDA's Botanical Guidance pathway. The company sells Mytesi (FDA-approved for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy) and Canalevia-CA1 (conditionally FDA-approved for chemotherapy-induced diarrhea in dogs), with a pipeline including crofelemer for cancer therapy-related diarrhea (Phase 3 OnTarget trial), rare intestinal failure diseases (MVID, SBS-IF) with orphan drug designation in the US and EU, and NP-300 for cholera-related diarrhea. The company also markets the Neonorm franchise (Foal, Calf, and the planned Dog launch) of plant-based non-prescription animal gut health products.

The business model combines direct prescription drug distribution, a US licensing arrangement with Woodward Specialty/Future Pak (January 2026 deal transferring US commercial rights for Mytesi and Canalevia-CA1 while retaining manufacturing, with $18M upfront plus up to $20M in milestones), FDA grant funding, and ongoing exempt securities offerings. Customer segments include adults with HIV/AIDS on antiretroviral therapy, cancer patients undergoing chemotherapy or targeted therapy, pediatric and adult patients with rare intestinal failure conditions (a population with no FDA-approved MVID treatment and high mortality), and veterinary oncology patients. The company serves the US market directly through its subsidiary Napo Pharmaceuticals, Europe through Napo Therapeutics S.P.A. (Milan, established 2021), and clinical sites in the UAE and Canada, with active clinical programs in the US, EU, and UAE.

Jaguar Health operates through wholly-owned subsidiaries (Napo Pharmaceuticals, Napo Therapeutics, Jaguar Animal Health) and a joint venture (Magdalena Biosciences with Filament Health for plant-based mental health and post-GLP-1 weight management candidates). The company maintains a proprietary sustainable Croton lechleri supply chain in Peru with over 800,000 trees planted since 2001 and fair-trade partnerships with Indigenous communities spanning more than two decades. Founded in 2017 through the merger of Napo Pharmaceuticals and Jaguar Animal Health (both entities founded by current CEO Lisa Conte, who also founded Shaman Pharmaceuticals in 1989), Jaguar Health trades on NASDAQ under the ticker JAGX and is headquartered in San Francisco, California. The company is in a turnaround posture following a 97.5% stock decline over the prior year, a 1-for-35 reverse stock split in April 2026, a 2025 net loss of $53.6 million, and the June 2026 Board-initiated exploration of strategic alternatives.

Name

Jaguar Health

Legal name

Jaguar Health, Inc.

Website

https://jaguar.health

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Jaguar Health is a commercial-stage pharmaceutical company that discovers, develops, and commercializes plant-based prescription medicines derived from the Croton lechleri Amazonian tree. Its lead compound crofelemer treats gastrointestinal distress in HIV/AIDS patients, cancer patients, and rare intestinal failure disease patients, alongside veterinary products.

Ownership category

akta.pro rank

Product category

Gastrointestinal Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industry

Digestive & Gut Health (Probiotics/Prebiotics/Enzymes) (HLAMALAC)

Keywords

• Plant-based pharmaceuticals
• Gastrointestinal therapeutics
• Antisecretory agents
• Veterinary digestive health
• Botanical drug development

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Prescription Drug Sales (Mytesi & Canalevia-CA1): Jaguar Health generates revenue from the sale of FDA-approved prescription drugs. Mytesi (crofelemer tablets) is approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Canalevia-CA1 (crofelemer delayed-release tablets) is conditionally approved for chemotherapy-induced diarrhea in dogs. Jaguar retains manufacturing responsibilities while Future Pak holds US marketing rights under a January 2026 licensing agreement. Q1 2026 net revenue was $20.2 million, representing 816% year-over-year growth driven by the licensing agreement.
2. US Licensing Agreement — Future Pak: In January 2026, Jaguar's subsidiary Napo Pharmaceuticals entered into a US licensing and supply arrangement with Woodward Specialty/Future Pak, granting exclusive US marketing rights for Mytesi and Canalevia-CA1. Jaguar received an $18 million upfront payment ($16 million received in January 2026 plus $3 million for buy-back provision termination), with up to $20 million in additional milestone and future payments. Jaguar continues to manufacture both drugs while Future Pak commercializes them.
3. Securities Offerings: Jaguar raises capital through exempt securities offerings. A $2.377 million exempt securities offering was conducted in September 2025. Additionally, a $3.448 million bridge financing round involved the CEO, board members, and institutional investors in March 2025.
4. FDA Grants: Jaguar receives non-dilutive grant funding from the FDA's Center for Veterinary Medicine. A $240,000 grant was awarded on January 1, 2026 to support ongoing effectiveness studies for Canalevia-CA1, the conditionally approved drug for chemotherapy-induced diarrhea in dogs.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Jaguar Health discovers, develops, and commercializes plant-based prescription medicines derived from the Amazonian Croton lechleri tree, with crofelemer as its flagship antisecretory compound. Its commercial portfolio includes Mytesi (FDA-approved for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy), Canalevia-CA1 (conditionally FDA-approved for chemotherapy-induced diarrhea in dogs), Gelclair (FDA-approved oral mucositis product), and the Neonorm plant-based non-prescription line for animal digestive health. The pipeline extends crofelemer into cancer therapy-related diarrhea, rare intestinal failure diseases (MVID, SBS-IF, CDD), and cholera (NP-300), with a whole leaf coca extract program in the Magdalena Biosciences joint venture for post-GLP-1 weight management.

Product overview

Jaguar Health is a commercial-stage pharmaceutical company that discovers, develops, and commercializes plant-based prescription medicines derived from the Croton lechleri tree. The company's product portfolio spans human and animal health. Human health products include Mytesi (FDA-approved for HIV-related diarrhea) and Gelclair (FDA-approved for oral mucositis), while crofelemer-based drugs are in development for cancer therapy-related diarrhea, short bowel syndrome with intestinal failure, and congenital diarrheal disorders. Animal health products include Canalevia-CA1 (conditionally approved for chemotherapy-induced diarrhea in dogs) and the Neonorm franchise (non-prescription digestive health products for dogs, foals, and calves). The company also has a joint venture, Magdalena Biosciences, developing a coca leaf extract for weight management. The pipeline includes crofelemer in multiple formulations targeting various gastrointestinal indications, and NP-300 for cholera-related diarrhea.

Differentiator

Problem solved

Functional benefit

Brands

• Napo Pharmaceuticals: Jaguar family company focused on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states.
• Napo Therapeutics
• Jaguar Animal Health
• Magdalena Biosciences
• Mytesi
• Canalevia-CA1
• Neonorm

Products and services

• Mytesi (crofelemer) FDA-approved prescription drug (crofelemer delayed-release tablets) for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. First-in-class antisecretory agent that modulates chloride secretion in the GI tract via CFTR and CaCC ion channels.
• Canalevia-CA1 (crofelemer) Conditionally FDA-approved veterinary prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, with crofelemer as the active pharmaceutical ingredient. Pivotal effectiveness study showed 77% of dog owners reported effectiveness and 40% reported complete resolution.
• Gelclair FDA-approved prescription oral mucositis product providing pain management for cancer patients, including those with head and neck cancers and patients undergoing bone marrow transplants. Promoted at the 2025 Oncology Nursing Society Congress by Napo Pharmaceuticals.
• Neonorm Foal Plant-based, non-prescription product derived from Croton lechleri tree extract to support normal stool formation, gut hydration, and bowel health in pre-weaned foals.
• Neonorm Calf Plant-based, non-prescription product derived from Croton lechleri tree extract to support normal stool formation, gut hydration, and bowel health in pre-weaned calves.
• Neonorm Dog Plant-based, non-prescription product designed to support normal stool formation, gut hydration, and bowel health in dogs, derived from sustainably harvested Croton lechleri tree extract. Extends the Neonorm franchise to the companion animal market.

Quantifiable outcome

• 77-83% of dog owners reported Canalevia-CA1 effective for treating chemotherapy-induced diarrhea; ~40% reported complete resolution of diarrhea symptoms
• +7 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Sheikh Khalifa Medical CityminorStrategic or Co-development Partner · 2 April 2026Sheikh Khalifa Medical City in Abu Dhabi, UAE is the site of an independent investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure patients, co-sponsored by Napo Pharmaceuticals. The study demonstrated groundbreaking results with parenteral support reductions ranging from 12 to 37% in patients with MVID and short bowel syndrome, with patients now on treatment for more than one year.
• Magdalena Biosciences (Jaguar Health + Filament Health JV)coreStrategic or Co-development Partner · 16 March 2026Magdalena Biosciences is a joint venture between Jaguar Health and Filament Health Corp. (a subsidiary of Red Light Holland), formed as part of Jaguar's Entheogen Therapeutics Initiative. The JV is developing novel prescription medicines derived from plants for mental health indications. In March 2026, the JV initiated a preclinical study of whole leaf coca extract for appetite suppression and post-GLP-1 weight management at the University of Calgary, with coca leaf sourced from Peru's ENACO. In June 2026, positive preclinical results showed the coca extract prevented weight gain in mice on a high-fat diet without reducing food intake or increasing physical activity.
• University of CalgaryminorStrategic or Co-development Partner · 16 March 2026Magdalena Biosciences initiated a preclinical study of whole leaf coca extract at the University of Calgary's Borgland Lab in Alberta, Canada in March 2026. The 20-day study evaluated the extract's effectiveness for appetite suppression and weight management. Results reported in June 2026 showed the extract prevented weight gain in mice on a high-fat diet without affecting food intake or physical activity.
• Woodward Specialty / Future PakcoreChannel Partner/ Reseller/ Distributor · 12 January 2026On January 12, 2026, Jaguar's subsidiary Napo Pharmaceuticals entered into a US licensing and supply arrangement with Woodward Specialty (affiliate of Future Pak), granting exclusive US marketing rights for Jaguar's crofelemer-based drugs Mytesi and Canalevia-CA1. Jaguar received an $18 million upfront payment plus up to $20 million in milestone payments. Jaguar retained manufacturing and supply responsibilities. The agreement aligns with Jaguar's strategy to focus crofelemer development on human rare-disease intestinal failure indications.
• ENACO (Empresa Nacional de La Coca, Peru)coreStrategic or Co-development PartnerENACO (Empresa Nacional de La Coca) is Peru's state company that provides coca leaf material for Magdalena Biosciences' preclinical studies and drug development program. The coca leaf is sourced under internationally recognized compliance requirements for the development of botanical prescription drug candidates. ENACO provides material for the post-GLP-1 weight management program and potential CNS indications being developed through the Jaguar-Filament JV.
• MD Anderson Cancer CenterminorStrategic or Co-development PartnerMD Anderson Cancer Center serves as the principal investigator site for Jaguar's pivotal Phase 3 OnTarget clinical trial evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. The trial is investigating crofelemer as an oral preventative treatment for cancer therapy-related diarrhea.
• Future PakcoreChannel Partner/ Reseller/ DistributorFuture Pak, LLC is Jaguar Health's exclusive US marketing partner for Mytesi and Canalevia-CA1 under a January 2026 licensing agreement. Future Pak received an upfront payment of $18 million plus additional milestone payments up to $20 million. Jaguar retained manufacturing and supply responsibilities. In March 2026, Jaguar received an additional $3 million from Future Pak following termination of a buy-back provision, allowing Future Pak to continue commercializing beyond the initial five-year window.
• Healing Forest ConservancyminorOthersThe Healing Forest Conservancy (HFC) is an independent nonprofit foundation established in 1990 to return benefits from product profits to collaborating countries and cultural groups. HFC promotes conservation of tropical forest biodiversity and the survival of traditional knowledge of medicinal plants. Jaguar's subsidiary Napo Pharmaceuticals is committed to distributing long-term benefits (percentage of product-related profits) to participating communities.

Scale indicators16 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Ardelyx: Small-cap specialty GI pharma commercializing Ibsrela (tenapanor) for IBS-C and Xphozah for hyperphosphatemia. Direct peer in GI specialty pharma with similar scale and pipeline focus on intestinal disorders.
• Phathom Pharmaceuticals: Specialty GI pharma commercializing Voquezna (vonoprazan) for GERD and H. pylori. Direct peer focused on novel mechanism GI therapies in similar commercial-stage profile.

Broad incumbents

• Ironwood Pharmaceuticals: GI specialty pharma that developed Linzess (linaclotide) for IBS-C/CIC, now part of AbbVie. Broad incumbent peer with overlapping antisecretory/GI mechanism expertise and substantially greater commercial scale.
• Bausch Health (Salix Pharmaceuticals): Bausch Health's Salix division is the leading GI specialty pharma unit (Xifaxan for IBS-D and hepatic encephalopathy). Broad incumbent comparable in GI specialty commercial focus and physician-facing sales model.
• Mallinckrodt Pharmaceuticals: Specialty/rare-disease pharma with experience commercializing therapies for highly specialized indications. Broad incumbent comparable to Jaguar's strategy of focusing on rare-disease IPF and high-unmet-need patient populations.
• Travere Therapeutics: Small-mid cap rare-disease pharma commercializing therapies in nephrology and metabolic rare disease. Broad incumbent peer in pursuing orphan-drug pathways and operating with constrained capital relative to large pharma.
• Takeda Pharmaceutical: Global rare-disease leader following the Shire acquisition, with significant GI and rare-disease infrastructure. Broad incumbent relevant to Napo Therapeutics' EU orphan-disease commercialization pathway.
• Zoetis: Global leader in animal health pharmaceuticals, including companion-animal GI products. Broad incumbent relevant to Jaguar Animal Health's Canalevia-CA1 and Neonorm franchises in veterinary GI.

Emerging players

• Entera Bio: Clinical-stage company developing oral peptides for hypoparathyroidism and other indications. Emerging player peer in the small-cap oral/intestinal therapeutics space with comparable capital constraints.
• Sebela Pharmaceuticals: Private specialty pharma with GI focus including IBS-C therapy (Zelnorm). Emerging player peer in specialty GI with similar niche positioning and focus on underserved GI conditions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/jaguar-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries4 records

Funding overview

Funding rounds18 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jaguar Health